13
November

08:00 AM EST

Medicinal Chemistry

Name: Medicinal Chemistry Strategy Meeting East Coast 2024 (Boston)
Start: 2024-11-13T08:00
End: 2024-11-13T18:00
Location: Crowne Plaza, London Docklands

Strategy Meeting East Coast USA 2024

Reinvigorating Productivity in Pharmarn Biotech Through Advanced Technologies and Innovative Techniques that Interrogate Activity and Mechanisms

Le Meridien Cambridge Boston

Our Event Starts In

–
days

–
hours

–
minutes

–
seconds

A MEETING EXPERIENCE UNLIKE ANY OTHER

Fresh Medicinal Chemistry Insights

Tired of the same conference experience? Real discussions and genuine networking are often promised, but not always delivered. Proventa International’s R&D Strategy Meetings are designed to avoid the pitfalls of a typical conference, by providing the right environment to make those important connections through interactive roundtable discussions, exclusive networking and keynote panel debates. Join Medicinal Chemistry professionals from across the East Coast, in Boston MA, to discover new insights and take your company’s mission to the next level.

What makes our strategy meetings unique?

Roundtable Discussions

Intimate discussions led by renowned industry experts. Have your voice heard and debate alongside like-minded life science executives.

Unrivalled Networking

With senior delegation from big pharma and innovative biotech from across the East Coast, you can network with peers from different locations, all in one place.

Personalised Agenda

Choose the topics that matter to you. Reserve your place at the roundtable discussions and ensure your whole day delivers the insights you need to hear.

Solutions to your Problems

We've partnered with the best solution providers to solve your biggest challenges. Engage in pre-arranged, private meetings to address your specific needs and find a tangible solution.

Industry Researched Topics

We guarantee our agenda is up-to-date and mission critical because its designed by you. We speak to our extended network of senior decision makers to ensure the most important topics are discussed.

Senior Decision Makers

The entire strategy meeting is specifically tailored to the needs and challenges of senior life science professionals. Discover how your peers are dealing with the same challenges as you.

Meet Our 2024 Facilitators

Our panel of facilitators play a key role in shaping the agenda for the day. See who will be bringing their expertise to the table at our Medicinal Chemistry strategy meeting.

Alex Nivorozhkin

Chief Scientific Officer Cybin

Andrew Zhang

Director, Head of Chemical Biology AstraZeneca

Benoit Moreau

Head of Medicinal Chemistry Remix Therapeutics

Blaise Lippa

SVP, Molecular Discovery Morphic Therapeutics

Changyun Hu

Head of Research Adept Therapeutics

Diane Joseph-McCarthy

Executive Director, Bioengineering Technology & Entrepreneurship Center Boston University

Dr. Tao Guo

SVP, Head of WuXi Chemistry - IDSU WuXi AppTec

Ed Olhava

Senior Vice President, Preclinical Development IFM Therapeutics

Over his nearly 20 year career in mid and early-stage biotech, Ed Olhava has invented and progressed multiple compounds through discovery and into clinical development. He has focused on discovering first-in-class small molecule modulators of new biological pathways, closely integrating medicinal chemistry, pharmacology, safety and CMC to enter clinical trials with these novel entities.
Before joining <a href="https://www.ifmthera.com/">IFM</a>, Ed was a strategic advisor at Third Rock Ventures, where he developed the strategic and operational plans for the drug discovery groups of two Third Rock seed companies, both of which were successfully funded and launched. Prior to Third Rock, he was a founding scientist at Epizyme, joining the company as the first medicinal chemist. He started the medicinal chemistry group and invented Epizyme’s first clinical compound and the first clinical histone methyltransferase inhibitor, EPZ-5676, leading activities from hit finding to filing the Investigational New Drug application. Before joining Epizyme, Ed began his medicinal chemistry career at Millennium Pharmaceuticals, where he co-invented NINLARO, approved in 2015 for the treatment of multiple myeloma, and MLN-4924.
Ed obtained his Ph.D. in synthetic organic chemistry from Harvard University and B.S. in chemistry from Stanford University. He is co-author/inventor on more than 40 papers and patents.

G. Joseph Franklin

Senior Vice President and Head of Early Discovery Anagenex

Jennifer Petter

Founder & CSO Arrakis Therapeutics

Jeremy Edmunds

Executive Director Immunology Chemistry AbbVie

Ken Lind

Senior Director, Head of Chemical Computing Sciences Jnana Therapeutics

Kenneth Duncan

VP, Chemistry Accent Therapeutics

Mark Ledeboer

SVP Drug Discovery Expansion Therapeutics

Michael Ellis

Senior Vice President, Head of Small Molecule Drug Discovery Bristol Myers Squibb

Mike Ellis is Senior Vice President and Head of the Small Molecule Drug Discovery organization at Bristol Myers Squibb. Mike partners with an interdisciplinary team of scientists toward the invention of new medicines. He has contributed to the discovery of multiple clinical assets, development candidates, and enabling tools and platforms. He is passionate about talent development and capitalizing on opportunities to impact human health through scientific innovation. Mike obtained a Bachelor of Science in Chemistry with honors, magna cum laude, from Wake Forest University, and a Ph.D. in Chemistry from the University of North Carolina at Chapel Hill. Following a Ruth L. Kirschstein National Institutes of Health Postdoctoral Fellowship at the University of California, Irvine, Mike began his career within the biopharmaceutical industry at Merck Research Laboratories. Mike received an American Chemical Society (ACS) Young Investigator’s Award in 2016, served as chair of the 2019 Boston Symposium on Organic & Bioorganic Chemistry, a member of the ACS Executive Committee from 2019-2022, co-chair of the 2022 ACS Pharma Leaders consortium, and chair of the 2023 Medicinal Chemistry Gordon Research Conference. He currently serves as a section editor for Medicinal Chemistry Reviews and as a board advisor in the biotechnology and scientific education sectors.

Monica Schenone

Head of Chemical Biology Pfizer

Richard Heidebrecht

Vice President and R&D Glycologix

Robert Goodnow

Head Drug Discovery Sciences Takeda

Shankar Venkatraman

Executive Director, Chemistry IFM Therapeutics

Over his 20+ year industrial career Shankar Venkatraman has invented and progressed multiple compounds through discovery and into clinical development. He has focused on discovering first-in-class small molecule modulators of new biological pathways, closely integrating medicinal chemistry, pharmacology, and safety to enter clinical trials with these novel entities. Before joining IFM Therapeutics, LLC, Shankar was a Director of Chemistry at Vitae Pharmaceuticals. There he led number of programs including Menin-MLL, resulting in Revumenib (SNDX-5613), currently undergoing multiple clinical trials for ALL/AML with an anticipated NDA filing by the end of 2023. Prior to Vitae, he was a Senior Research Fellow at Merck, where he worked on number of modalities including HIV, neuropathic pain and schizophrenia, and delivered number of clinical candidates. Before joining Merck, Shankar began his medicinal chemistry career at Axys Pharmaceuticals, and worked on cathepsin K, with efforts leading to the identification of Odanacatib. Shankar obtained his Ph.D. in synthetic organic chemistry from University of Minnesota and B.S. in chemistry from University of Bombay. He is co-author/inventor on more than 60 papers and patents.

2024 AGENDA

See Which Topics Are Discussed at the Strategy Meeting

09:00 - 10:00

Roundtable Tracks

AI/ML
Looking into the Pivotal Role of AI in Drug Discovery

-Diane Joseph-McCarthy
Executive Director, Bioengineering Technology & Entrepreneurship Center
Boston University

Innovative and Emerging Modalities
Challenges and solutions in the hit-tolead phase: ensuring efficacy and safety in drug development

-Benoit Moreau
Head of Medicinal Chemistry
Remix Therapeutics

Chemical Biology, Targeted Protein Degradation & Undruggables
Pioneering Chemical and Proteomics Approaches: Unraveling Efficacy and Safety in Small Molecule and Protein Degradation Across Multiple Therapeutic Frontiers

-Andrew Zhang
Director, Head of Chemical Biology
AstraZeneca

Hit Identification / Lead Optimization
From Hits to Leads: Advanced Strategies and Technologies for Enhancing Drug Discovery in the Initial Phases

-Richard Heidebrecht
Vice President and R&D
Glycologix

Design & Synthesis
Streamlining the hit-to-candidate process: Strategies to most effectively advance chemical matter from hit to clinical candidate

-Shankar Venkatraman
Executive Director, Chemistry
IFM Therapeutics

Integrated Drug Discovery
Addressing the Unmet Needs in CNS Drug Discovery: New Paradigms in Target Identification and Drug Development

-Alex Nivorozhkin
Chief Scientific Officer
Cybin

11:10 - 12:10

Roundtable Tracks

AI/ML
Leveraging Generative Modeling to Accelerate Drug Discovery

Sponsor

Innovative and Emerging Modalities
Examining the Mechanism and Effects of Induced Proximity Modalities

Sponsor

Chemical Biology, Targeted Protein Degradation & Undruggables
Methods of Computation and Cheminformatics for Chemical Synthesis and Hit Finding for Tough Targets and New Therapeutic Approaches

WuXi AppTec

Hit Identification / Lead Optimization
Innovative Approaches to Lead Optimization: Integrating Computational Methods and Machine Learning in Small Molecule Design

Sponsor

Design & Synthesis
Exploiting the Selectivity and Efficiency of Enzymes in Complex Molecule Synthesis

Sponsor

Integrated Drug Discovery
The Convergence of AI and Drug Discovery: Innovative Approaches to Accelerating the Development Pipeline

Sponsor

12:15 - 13:15

Roundtable Tracks

AI/ML
The Evolution of AI: Looking Back at the Past 10 years and Projecting the Future 10

Innovative and Emerging Modalities
Beyond Small Molecules: The Rise of Biologics and Biosimilars in Modern Therapeutics

-Robert Goodnow
Head Drug Discovery Sciences
Takeda

Chemical Biology, Targeted Protein Degradation & Undruggables
Exploring the Current Formulation Challenges in Undruggable Leads

-Ed Olhava
Senior Vice President, Preclinical Development
IFM Therapeutics

Hit Identification / Lead Optimization
The Evolution of Hit-to-Lead Paradigms: Combining Traditional Approaches with Modern Innovations in Small Molecule Research

-G. Joseph Franklin
Senior Vice President and Head of Early Discovery
Anagenex

Design & Synthesis
The Best Methods for Synthesizing Quantities Ranging From Milligrams To Kilograms

-Kenneth Duncan
VP, Chemistry
Accent Therapeutics

Integrated Drug Discovery
RNA as a Drug Target: Breakthroughs and Challenges in Small Molecule Approaches

-Jennifer Petter
Founder & CSO
Arrakis Therapeutics

14:40 - 15:10

Formulation Development Strategies for Poorly Soluble Compounds

15:10 - 16:10

Roundtable Tracks

AI/ML
Revolutionizing Drug Discovery: Unleashing AI and Generative Modeling for Molecular Innovation

-Jeremy Edmunds
Executive Director Immunology Chemistry
AbbVie

Innovative and Emerging Modalities
Revolutionizing Healthcare: How Small Molecules are Shaping the Future of Emerging Therapeutic Modalities

-Michael Ellis
Senior Vice President, Head of Small Molecule Drug Discovery
Bristol Myers Squibb

Chemical Biology, Targeted Protein Degradation & Undruggables
Understanding Protein Degradation Pathways and Implications for Biologics Stability and Efficacy

-Monica Schenone
Head of Chemical Biology
Pfizer

Hit Identification / Lead Optimization
The Evolution of Hit-to-Lead Paradigms: Combining Traditional Approaches with Modern Innovations in Small Molecule Research

-Blaise Lippa
SVP, Molecular Discovery
Morphic Therapeutics

Design & Synthesis
Emerging Techniques in Peptide and Protein Synthesis

Integrated Drug Discovery
Emerging Modalities in Integrated Drug Discovery: Turning the Tide on Undruggable Proteins

-Ken Lind
Senior Director, Head of Chemical Computing Sciences
Jnana Therapeutics

See the full agenda and facilitator line-uprnDownload the strategy meeting brochure for full details

DOWNLOAD THE BROCHURE

Reasons To Attend the Strategy Meeting

Discussions on the advancements in targeted protein degradation andrnpushing past its boundaries.

Leveraging Artificial Intelligence and Machine Learning in accelerating therndevelopment of new drugs

Discuss approaches to further understand the interactions of undruggablerntargets and different Protein Degraders such as PROTACs, Molecular Glues,rnetc

Focusing on advancing interrogative techniques to improve the Drug Delivery System/Discovery: Modified mRNA, Nanoparticle-Mediated siRNA, Antibody-Drug Conjugates, and more

Become an official strategy meeting partner Whatever your business needs, we can help. Get in touch for partnering opportunities

I'D LIKE TO PARTNER

Press play to hear what your colleagues had to say...

Hotel & Venue

Le Méridien Boston Cambridge

Le Méridien Cambridge-MIT’s elegant guest rooms and suites offer a place of luxurious sanctuary and unmatched comfort. Explore unique programs inspired by the brand’s European heritage. Born in a glamorous era of travel, Le Méridien believes everyone should explore the world in style.

Hotel Details Maps & Direction Parking

Quick Links

Want to find out more?

Find out more details about our Strategy Meetings and other news and events.

Here To Help

Want to know more? Interested in sponsoring the event? Need help registering your team? Just get in touch and a member of the team will be happy to help.

14 May 2024

Drug Discovery Biology & Bioinformatics Strategy Meeting East Coast USA 2024

21 May 2024

Drug Discovery Biology & Bioinformatics Strategy Meeting West Coast USA 2024

16 May 2024

Clinical Operations and Clinical Trial Supply Chain Strategy Meeting East Coast USA 2024

23 May 2024

Clinical Operations and Clinical Trial Supply Chain Strategy Meeting West Coast USA 2024

15 May 2024

Medicinal Chemistry Strategy Meeting East Coast USA 2024

22 May 2024

Medicinal Chemistry Strategy Meeting West Coast USA 2024

Europe

USA East

USA West

Webinars

Dinners & Spotlights

R&D

R&D Boston

Drug Discovery Biology Strategy Meeting East Coast – Boston 2024

Medicinal Chemistry

Strategy Meeting East Coast USA 2024

<img class="lazy" decoding="async" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%201%201'%3E%3C/svg%3E" data-src="https://proventainternational.com/wp-content/uploads/2020/12/location.png" >Le Meridien Cambridge Boston

Fresh Medicinal Chemistry Insights

What makes our strategy meetings unique?

Roundtable Discussions

Unrivalled Networking

Personalised Agenda

Solutions to your Problems

Industry Researched Topics

Senior Decision Makers

Meet Our 2024 Facilitators

Alex Nivorozhkin

Andrew Zhang

Benoit Moreau

Blaise Lippa

Changyun Hu

Diane Joseph-McCarthy

Dr. Tao Guo

Ed Olhava

G. Joseph Franklin

Jennifer Petter

Jeremy Edmunds

Ken Lind

Kenneth Duncan

Mark Ledeboer

Michael Ellis

Monica Schenone

Richard Heidebrecht

Robert Goodnow

Shankar Venkatraman

2024 AGENDA

See Which Topics Are Discussed at the Strategy Meeting

Breakfast & Registration

Opening Keynote Presentation

Roundtable ( Pharma/Biotech )

Roundtable Tracks

NETWORKING / 1-1 MEETINGS

NETWORKING / 1-1 MEETINGS

NETWORKING / 1-1 MEETINGS

Roundtable ( Solutions )

Roundtable Tracks

Sponsor

Sponsor

WuXi AppTec

Sponsor

Sponsor

Sponsor

Roundtable ( Pharma/Biotech )

Roundtable Tracks

NETWORKING LUNCH

Networking / 1-1 Meetings

AFTERNOON KEYNOTE PRESENTATION

Formulation Development Strategies for Poorly Soluble Compounds

Roundtable ( Pharma/Biotech )

Roundtable Tracks

AFTERNOON REFRESHMENT BREAK

KEYNOTE PRESENTATION

PANEL DISCUSSION

Drinks & Canapes Reception

14
May
2024

21
May
2024

16
May
2024

23
May
2024

15
May
2024

22
May
2024

Le Meridien Cambridge Boston